 WALTHAM, Mass. and STOCKHOLM, Sweden, Oct. 15, 2021 GLOBE NEWSWIRE -- Apellis Pharmaceuticals, Inc. Nasdaq: APLS and Swedish Orphan Biovitrum AB publ SobiTM STO:SOBI announced today that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency has adopted a positive opinion recommending the marketing authorization of Aspaveli pegcetacoplan for the treatment of adults with paroxysmal nocturnal hemoglobinuria PNH who are anemic after treatment with a C5 inhibitor for at least three months. The positive opinion from the CHMP is now referred to the European Commission for an approval decision. 